{"name":"Servier (Tianjin) Pharmaceutical Co. LTD.","slug":"servier-tianjin-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"Servier Laboratories is an international pharmaceutical company founded by Jacques Servier and now governed by a non-profit foundation, with its headquarters in France (Suresnes).","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Gliclazide MR and Insulin Glargine Injection","genericName":"Gliclazide MR and Insulin Glargine Injection","slug":"gliclazide-mr-and-insulin-glargine-injection","indication":"Other","status":"marketed"},{"name":"Biosynthetic Human Insulin Injection","genericName":"Biosynthetic Human Insulin Injection","slug":"biosynthetic-human-insulin-injection","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Gliclazide MR and Insulin Glargine Injection","genericName":"Gliclazide MR and Insulin Glargine Injection","slug":"gliclazide-mr-and-insulin-glargine-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Biosynthetic Human Insulin Injection","genericName":"Biosynthetic Human Insulin Injection","slug":"biosynthetic-human-insulin-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBFV25MYXRGYTJDTC1PNjd4OXBuN2VSdHAxWll5am5CV1AxZXFfMG1lREhXc3JBNFMyYW15NWh3S1ZwRHV6c0MxM2psTVp2NXg0ZUJWeFlrWUlTTUxRT196NFl2dE9hMmxnalE1VVR6cTNvd3VuTFUtV3ZvSQ?oc=5","date":"2025-06-02","type":"pipeline","source":"Servier","summary":"China, the new epicenter of global pharmaceutical innovation - Servier","headline":"China, the new epicenter of global pharmaceutical innovation","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}